Correspondence 0001683168-22-008046 from CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals, Inc.
Date: Nov. 28, 2022 · CIK: 0001729427 · Accession: 0001683168-22-008046

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-267975

Date

November 28, 2022

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

CNS Pharmaceuticals, Inc.

Letter

Re: CNS Pharmaceuticals, Inc.

November 28, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Registration Statement on Form S-1 (Registration No. 333-267975) - Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statement on Form S-1 (333-267975) (the “Registration Statement”), hereby concurs in the request by CNS Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as practicable thereafter, on November 29, 2022, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

November 28, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

    Re:
    CNS Pharmaceuticals, Inc.

    Registration Statement on Form S-1 (Registration No. 333-267975) - Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co.,
LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration
statement on Form S-1 (333-267975) (the “Registration Statement”), hereby concurs in the request by CNS Pharmaceuticals, Inc.
that the effective date of the above-referenced registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as
practicable thereafter, on November 29, 2022, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware
of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/ Edward D. Silvera

       Name: Edward D. Silvera

       Title: Chief Operating Officer

430 Park Avenue | New York, NY 10022 | 212.356.0500
| www.hcwco.com

Member: FINRA/SIPC

SecProbe.io